J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper,Nancy E. Davidson,Dana S. Wollins,Douglas W. Blayney,Adam P. Dicker,Patricia A. Ganz,J. Russell Hoverman,Robert M. Langdon,Gary H. Lyman,Neal J. Meropol,Therese M. Mulvey,Lee N. Newcomer,Jeffrey Peppercorn,Blase N. Polite,Derek Raghavan,Gregory Rossi,Leonard B. Saltz,Deborah Schrag,Thomas J. Smith,Peter Paul Yu,Clifford A. Hudis,Julie M. Vose,Richard L. Schilsky +22 more
TL;DR: The value framework has been constructed as a conceptual model that incorporates the elements of clinical benefit, toxicity, and symptom palliation as derived from a comparative clinical trial and combines these elements into a score termed the net health benefit (NHB).
Book
Non-Hodgkin's Lymphomas
Andrew D. Zelenetz,Ranjana H. Advani,John C. Byrd,Myron S. Czuczman,Lloyd E. Damon,Madeleine Duvic,Luis Fayad,Andres Forero,Martha Glenn,Jon P. Gockerman,Leo I. Gordon,Nancy L. Harris,Richard T. Hoppe,Steven M. Horwitz,Mark S. Kaminski,Youn H. Kim,Ann S. LaCasce,A P Nademanee,Elise Olsen,Pierluigi Porcu,Oliver W. Press,Leonard R. Prosnitz,Mitchell R. Smith,Eduardo M. Sotomayor,Julie M. Vose,Joachim Yahalom,Furhan Yunus +26 more
TL;DR: In this article, different subtypes of non-Hodgkin's lymphoma (NHL) were compared using histological and immunohistochemical methods, including the normal lymph node structure and function.
Journal ArticleDOI
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer,Kai Fu,Timothy C. Greiner,Lynette M. Smith,Jan Delabie,Randy D. Gascoyne,German Ott,Andreas Rosenwald,Rita M. Braziel,Elias Campo,Julie M. Vose,Georg Lenz,Louis M. Staudt,Wing C. Chan,Dennis D. Weisenburger +14 more
TL;DR: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.
Journal ArticleDOI
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma
Julie M. Vose,Brian K. Link,Michael L. Grossbard,M. Czuczman,A. Grillo-Lopez,P. Gilman,A. Lowe,L. A. Kunkel,R. I. Fisher +8 more
TL;DR: This is the first report to demonstrate the safety and efficacy of the Rituxan chimeric anti-CD20 antibody in combination with standard-dose CHOP in the treatment of aggressive B-cell lymphoma.
Journal ArticleDOI
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Javeed Iqbal,George E. Wright,Chao Wang,Andreas Rosenwald,Randy D. Gascoyne,Dennis D. Weisenburger,Timothy C. Greiner,Lynette M. Smith,Shuangping Guo,Ryan A. Wilcox,Bin Tean Teh,Soon Thye Lim,Soon Yong Tan,Lisa M. Rimsza,Elaine S. Jaffe,Elias Campo,Antonio Martinez,Jan Delabie,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,German Ott,Eva Geissinger,Philippe Gaulard,Pier Paolo Piccaluga,Stefano Pileri,Wing Yan Au,Shigeo Nakamura,Masao Seto,Françoise Berger,Laurence de Leval,Joseph M. Connors,James O. Armitage,Julie M. Vose,Wing C. Chan,Louis M. Staudt +35 more
TL;DR: Gene-expression profiles, immunohistochemistry, and IDH2 mutation analysis in reclassified cases supported the validity of the reclassification of PTCL-NOS cases, and high expression of several signatures associated with the tumor microenvironment was significantly associated with outcome.